

Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

BioActive Human BCOR oncogenic mutation Recombinant Protein,Fc Tag

Catalog Number:SGRP00668

DESCRIPTION	
Product Name	BioActive Human BCOR oncogenic mutation Recombinant Protein,Fc Tag
Gene Name	BCOR
Source	Full length Human BCL2 amplification, expressed in HEK293 cells.
Alternative names	
SPECIFICATIONS	
Biological Activity	Fully biologically active
Purity	> 95% by SDS-PAGE & HPLC
Endotoxin Level	< 1.0 EU per μg protein as determined by the LAL method
Expression System	HEK293 Cells
Format	Recombinant
Species	Human
Predicted MW	
Actual MW	
Applications	Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLO
Form	Lyophilized from sterile PBS, pH 7.51
Concentration	N/A
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute with Phosphate Buffered Saline.
BACKGROUND	
Gene Accession	Q6W2J9
Gene Alias	Protein names Recommended name BCL-6 corepressor Short names BCoR Gene names Name BCOR Synonyms KIAA1575



Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

myelodysplastic syndrome. BCOR internal tandem duplications (ITD) are present in more than 75% of CCSK, a pediatric renal sarcoma.

Background

BCOR is a gene that encodes for an epigenetic regulator involved in the specification of cell differentiation and body structure development and takes part in the noncanonical polycomb repressive complex 1. BCOR mutations are found in aggressive B3-thymomas, adenoid cystic carcinoma, uterine corpus endometrial carcinoma, EBV + gastric carcinomas, colon and stomach adenocarcinoma, and lung tumors, regardless of histology. Loss-of-function mutations of BCOR are present in around 10% of unselected acute myeloid leukemia and